Clinical Research Alliance Inc | Lake Success, NY

Research site

(Unclaimed)

Location

2002 Marcus Avenue Suite N200, Lake Success, New York, United States of America

Site insights

Top conditions

Top treatments

INCB050465

Carboplatin

Sunitinib

Gemcitabine

Neratinib

Abraxane

Fulvestrant

Abiraterone Acetate

Zandelisib

LEE011

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 32 total trials

A Study of ICP-192 in Patients With Advanced Solid Tumors

This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. I...

Enrolling

Advanced Solid Tumors

Urothelial Carcinoma

Drug: Drug ICP-192

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Enrolling

Small Cell Lung Cancer

Drug: Topotecan

Drug: Amrubicin

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting

Metastatic Adenocarcinoma of the Pancreas

Drug: Leucovorin

Drug: Gemcitabine

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...

Enrolling

Diffuse Large B-cell Lymphoma

Drug: Selinexor

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat...

Active, not recruiting

Follicular Lymphoma

Drug: Abexinostat

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single ag...

Enrolling

Hematologic Malignancies

Drug: venetoclax

Drug: SLS009

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combinati...

Active, not recruiting

Squamous Non Small Cell Lung Cancer

Nonsquamous Non Small Cell Lung Cancer

Drug: Etrumadenant

Drug: Zimberelimab